Monocyte Chemoattractant Protein-1/CCL2 As a Biomarker in Acute Coronary Syndromes

Overview

Journal Curr Atheroscler Rep

Publisher Springer

Specialty Cardiology & Vascular Diseases

Date 2009 Feb 21

PMID 19228487

Citations 29

Authors

Carlos Gonzalez-Quesada

Nikolaos G Frangogiannis

Affiliations

Soon will be listed here.

Abstract

The CC chemokine monocyte chemoattractant protein (MCP)-1/CCL2 is involved in the formation, progression, and destabilization of atheromatous plaques and plays an essential role in postinfarction remodeling. These properties generated significant interest in the potential significance of MCP-1 as a biomarker in acute coronary syndromes (ACS). Emerging evidence suggests that MCP-1 plasma levels have prognostic value in the acute and chronic phase following ACS, providing information independent of standard clinical variables. The mechanisms responsible for adverse prognosis in patients with elevated plasma MCP-1 following ACS remain unknown. High plasma MCP-1 levels may reflect a higher burden of atherosclerotic disease, may exert prothrombotic effects resulting in recurrent coronary events, or may identify patients who mount a more intense cardiac inflammatory reaction following a coronary event, resulting in enhanced adverse remodeling. Beyond its prognostic significance, the MCP-1 axis may be an attractive target for therapy in patients with ACS.

Citing Articles

Long-Term Prognostic Value of Adipocytokines in Patients with Acute Coronary Syndrome: An 8-Year Clinical Prospective Cohort Study.

Wang X, Bu H, Wei C, Liu J, Qi Y, Shan W J Inflamm Res. 2024; 17:6989-7003.

PMID: 39372586 PMC: 11456299. DOI: 10.2147/JIR.S483600.

Determining the association of inflammatory markers, cell-adhesion molecules, and endothelial dysfunction biomarkers with ACS in Indian population.

Kale K, Rajage H, G R K Indian Heart J. 2024; 76(1):63-66.

PMID: 38301959 PMC: 10943524. DOI: 10.1016/j.ihj.2024.01.016.

Alterated gene expression in dilated cardiomyopathy after left ventricular assist device support by bioinformatics analysis.

Wei Y, Cao H, Peng Y, Zhang B Front Cardiovasc Med. 2023; 10:1013057.

PMID: 37008310 PMC: 10063844. DOI: 10.3389/fcvm.2023.1013057.

A Hypomethylating Ketogenic Diet in Apolipoprotein E-Deficient Mice: A Pilot Study on Vascular Effects and Specific Epigenetic Changes.

Castro R, Whalen C, Gullette S, Mattie F, Florindo C, Heil S Nutrients. 2021; 13(10).

PMID: 34684577 PMC: 8537671. DOI: 10.3390/nu13103576.

Cholesterol loading suppresses the atheroinflammatory gene polarization of human macrophages induced by colony stimulating factors.

Lappalainen J, Yeung N, Nguyen S, Jauhiainen M, Kovanen P, Lee-Rueckert M Sci Rep. 2021; 11(1):4923.

PMID: 33649397 PMC: 7921113. DOI: 10.1038/s41598-021-84249-y.

References

Morrow D, Rifai N, Antman E, Weiner D, McCabe C, Cannon C . C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1998; 31(7):1460-5. DOI: 10.1016/s0735-1097(98)00136-3. View

Doyle B, Caplice N . Plaque neovascularization and antiangiogenic therapy for atherosclerosis. J Am Coll Cardiol. 2007; 49(21):2073-80. DOI: 10.1016/j.jacc.2007.01.089. View

Nelken N, Coughlin S, Gordon D, Wilcox J . Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest. 1991; 88(4):1121-7. PMC: 295565. DOI: 10.1172/JCI115411. View

Nathan C . Points of control in inflammation. Nature. 2002; 420(6917):846-52. DOI: 10.1038/nature01320. View

Aukrust P, Yndestad A, Smith C, Ueland T, Gullestad L, Damas J . Chemokines in cardiovascular risk prediction. Thromb Haemost. 2007; 97(5):748-54. View

Dawson T, Kuziel W, Osahar T, Maeda N . Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis. 1999; 143(1):205-11. DOI: 10.1016/s0021-9150(98)00318-9. View

Hoogeveen R, Morrison A, Boerwinkle E, Miles J, Rhodes C, Sharrett A . Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study. Atherosclerosis. 2005; 183(2):301-7. DOI: 10.1016/j.atherosclerosis.2005.03.007. View

Lau E, Paavola C, Johnson Z, Gaudry J, Geretti E, Borlat F . Identification of the glycosaminoglycan binding site of the CC chemokine, MCP-1: implications for structure and function in vivo. J Biol Chem. 2004; 279(21):22294-305. DOI: 10.1074/jbc.M311224200. View

Charo I, Taubman M . Chemokines in the pathogenesis of vascular disease. Circ Res. 2004; 95(9):858-66. DOI: 10.1161/01.RES.0000146672.10582.17. View

10.

Nishiyama K, Ogawa H, Yasue H, Soejima H, Misumi K, Takazoe K . Simultaneous elevation of the levels of circulating monocyte chemoattractant protein-1 and tissue factor in acute coronary syndromes. Jpn Circ J. 1998; 62(9):710-2. DOI: 10.1253/jcj.62.710. View

11.

Aukrust P, Berge R, Ueland T, Aaser E, Damas J, Wikeby L . Interaction between chemokines and oxidative stress: possible pathogenic role in acute coronary syndromes. J Am Coll Cardiol. 2001; 37(2):485-91. DOI: 10.1016/s0735-1097(00)01110-4. View

12.

Gerard C, Rollins B . Chemokines and disease. Nat Immunol. 2001; 2(2):108-15. DOI: 10.1038/84209. View

13.

McDermott D, Yang Q, Kathiresan S, Cupples L, Massaro J, Keaney Jr J . CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study. Circulation. 2005; 112(8):1113-20. DOI: 10.1161/CIRCULATIONAHA.105.543579. View

14.

Gosling J, Slaymaker S, Gu L, Tseng S, Zlot C, Young S . MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest. 1999; 103(6):773-8. PMC: 408147. DOI: 10.1172/JCI5624. View

15.

Inoue S, Egashira K, Ni W, Kitamoto S, Usui M, Otani K . Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice. Circulation. 2002; 106(21):2700-6. DOI: 10.1161/01.cir.0000038140.80105.ad. View

16.

Libby P . Atherosclerosis: disease biology affecting the coronary vasculature. Am J Cardiol. 2006; 98(12A):3Q-9Q. DOI: 10.1016/j.amjcard.2006.09.020. View

17.

Ceradini D, Kulkarni A, Callaghan M, Tepper O, Bastidas N, Kleinman M . Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004; 10(8):858-64. DOI: 10.1038/nm1075. View

18.

Frangogiannis N . The mechanistic basis of infarct healing. Antioxid Redox Signal. 2006; 8(11-12):1907-39. DOI: 10.1089/ars.2006.8.1907. View

19.

Gu L, Okada Y, Clinton S, Gerard C, Sukhova G, Libby P . Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell. 1998; 2(2):275-81. DOI: 10.1016/s1097-2765(00)80139-2. View

20.

Rezaie-Majd A, Maca T, Bucek R, Valent P, Muller M, Husslein P . Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2002; 22(7):1194-9. DOI: 10.1161/01.atv.0000022694.16328.cc. View